Log in to search using one of your social media accounts:


NaviGate touts 1st 52mm transcatheter tricuspid valve procedure

NaviGate Cardiac Structures touted this week that its Gate catheter-guided tricuspid atrioventricular valved stent was implanted six weeks ago into a patient’s transplanted heart. The patient’s transplanted heart was failing due to severe tricuspid valve insufficiency. The successful implantation at the Policlinico of the University of Padua, Italy, is the first European-based patient treated with the company’s tricuspid replacement heart valve. Three hours after the procedure, the patient was showing improved renal function, NaviGate reported. Two months after the intervention, the 67-year-old male patient has improved clinically and boasts excellent valvular function, according to the company. This procedure brings the total number of NaviGate tricuspid implant cases that haven’t resulted in death after 30 days to three. The patient received a heart transplant in 1990 for post-ischemic dilated cardiomyopathy, the company said, and had an array of comorbidities. Since the start of this year, he has reportedly had five hospitalizations for heart failure due to severe regurgitation of the tricuspid valve in his transplanted heart. The patient was released five days after he received NaviGate’s replacement heart valve. “This is the first size-52 mm Gate tricuspid AVS implanted, and the first tricuspid valve replacement in a failing transplanted heart in one of the leading cardiac centers in Europe. Our team is working diligently to reach the ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Implants Cardiovascular NaviGate Cardiac Structures Inc Source Type: news

Related Links:

Condition:   Valve Heart Disease Interventions:   Other: MRI;   Other: Transthoracic echocardiography exam Sponsors:   CryoLife, Inc.;   Northwestern University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Osteochondral; Defect Interventions:   Procedure: autologous osteo-periosteal cylinder graft transplantation;   Procedure: autologous osteochondral graft transplantation Sponsor:   Peking University Third Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: BMJ Comments - Category: General Medicine Source Type: forums
Medtronic (NYSE:MDT) said today it won FDA approval for its portfolio of Azure pacemakers with BlueSync patient monitoring technology. The clearances cover both the Azure XT MRI and Azure S MRI pacers including single chamber and dual chamber models, the Fridley, Minn.-based company said. The newly cleared pacers have estimated lifespans of 13.7 years for dual chamber pacers, which Medtronic estimates is 27% longer than the earlier-gen devices. The Azure portfolio of pacers feature the company’s Reactive ATP algorithm intended to slow the progression of atrial fibrillation and BlueSynch technology which allows f...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Medtronic Source Type: news
In conclusion, the data presented in this paper should prompt other population studies focused on DRB3/4/5 genes and be used as a basis for future investigations of the clinical relevance of these genes in transplantation setting.
Source: Tissue Antigens - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
DIABETES sufferers are more at risk of dying from heart failure, says new study.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Calorie restriction improves health and extends life in most species and lineages tested, while both Protein restriction and intermittent fasting can provide similar but usually lesser packages of benefits. Once delving into the details of the biochemistry involved, however, the picture becomes very complex, and is still quite uncertain. These strategies probably work through overlapping collections of mechanisms that in turn interact with one another. Intermittent fasting and protein restriction still provide some benefits even when calorie level is kept constant, for example, and assays of epigenetic changes look fairly ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
The ever expanding epidemic of end-stage heart failure represents one of the greatest challenges of modern cardiovascular medicine. With medical treatments hampered by significant limitations, physicians caring for patients with advanced heart disease have turned to cardiac transplantation and durable mechanical circulatory assist devices as definitive therapies. These advanced therapeutic modalities are not widely available outside the United States and Europe, but nevertheless offer enormous potential for patients in the Arab Gulf suffering from end-stage heart failure. This review will discuss the management of end-stag...
Source: Annals of Saudi Medicine - Category: General Medicine Tags: ISSUE 6 Source Type: research
Abstract BackgroundThere are sparse clinical data on the procedural trends, outcomes and readmission rates following FDA approval and expansion of Transcatheter mitral valve repair/MitraClip®. Whether a complex new technology can be disseminated safely and quickly is controversial. MethodsThe study cohort was derived from the National Readmission Data (NRD) 2013–14. MitraClip® was identified using appropriate International Classification of Diseases, 9th Revision, Clinical Modification (ICD‐9‐CM) codes. The primary outcome was a composite of in‐hospital mortality + procedural complications...
Source: Catheterization and Cardiovascular Interventions - Category: Cardiovascular & Thoracic Surgery Authors: Tags: VALVULAR AND STRUCTURAL HEART DISEASES Source Type: research
AbstractLiver failure is one of the main risks of death worldwide, and it originates from repetitive injuries and inflammations of liver tissues, which finally leads to the liver cirrhosis or cancer. Currently, liver transplantation is the only effective treatment for the liver diseases although it has a limitation due to donor scarcity. Alternatively, cell therapy to regenerate and reconstruct the damaged liver has been suggested to overcome the current limitation of liver disease cures. Several transplantable cell types could be utilized for recovering liver functions in injured liver, including bone marrow cells, mesenc...
Source: Tissue Engineering and Regenerative Medicine - Category: Biotechnology Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Clinical Trials | Dilated Cardiomyopathy | Heart | Heart Failure | Heart Transplant | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Italy Health | Transplant Surgery | Transplants